ImmuPharma plc (AIM:IMM)

Market Cap	9.32M
Revenue (ttm)	n/a
Net Income (ttm)	-2.48M
Shares Out	499.72M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,309,649
Average Volume	1,492,863
Open	1.970
Previous Close	1.875
Day's Range	1.800 - 2.076
52-Week Range	0.850 - 7.400
Beta	2.58
RSI	29.07
Earnings Date	Aug 5, 2025

About ImmuPharma

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired aut...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 6
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: IMM